NEJM/X
Sep 30, 2025, 06:42
HI-PRO Trial: Apixaban for Long-Term Prevention of Recurrent VTE
The New England Journal of Medicine (NEJM) has shared a post on X:
“In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results and Research Summary.”
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison
Read the full paper here.
Find more on Hemostasis Today.
-
Mar 5, 2026, 17:48Estelle Carminita։ What If the Origin of Platelet Dysfunction Starts in the Bone Marrow
-
Mar 5, 2026, 17:43Pierre Sabouret: The Best Antithrombotic Strategy in Patients with Atherosclerotic Stroke and AF
-
Mar 5, 2026, 17:37John Abraham։ The Role of Diagnostic Splenectomy in Unexplained Splenomegaly
-
Mar 5, 2026, 17:31Fayad Al-Haimus: Key Themes from the New 2026 AHA/ACC Guideline for Acute PE
-
Mar 5, 2026, 16:56From Chronic Pain with Every Step to Exercising Every Day – EHC
-
Mar 5, 2026, 15:51Samer Al Hadidi: Cytopenias and Infection Risk With BCMA-Directed Bispecific Antibodies
-
Mar 5, 2026, 15:35Ney Carter Borges: Cholesterol-Inflammation Fusion in Atherosclerosis
-
Mar 5, 2026, 15:33Nicolas Hubacz: How Stress Shapes Organ Development
-
Mar 5, 2026, 15:28Charles Greenberg: What If D-dimer Isn’t ‘Non-Specific’ At All?